This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Glionix

NovaRx Corporation

Drug Names(s): Glionix, Ranagengliotucel-L

Description: Glionix is a vaccine consisting of autologous TGF-b2 antisense-modified tumor cells.

Deal Structure: Viropro and NovaRx
In October 2015, Viropro signed a non-binding Letter of Intent (LOI) for the acquisition of NovaRx in an all-stock transaction that is expected to close by year-end, subject to the approval by both companies of definitive documents and the achievement of certain other milestones.


Glionix News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug